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Abstract
Immunocontraception has been proposed as a tool for managing African elephant populations threatening to 
ʻoutgrow  ʼa wildlife reserve. To date, however, the only immunocontraceptive technique tested on elephant 
cows is porcine zona pellucida (pZP) vaccination, in which solubilized pZP is injected together with an adju-
vant to induce formation of circulating antizona pellucida antibodies, which block fertilization. A review of 
the literature on the use of pZP vaccination in free-ranging mammals reveals that the contraceptive efficacy 
ranges between 22% and 100% (15 trials, 2 in elephants). A pZP vaccine can be delivered by dart, but at 
present more than one inoculation is needed to ensure contraceptive antibody titres. Initial studies in elephants 
suggest that pZP vaccination is safe, even in pregnant animals, does not pass through the food chain and is 
reversible, at least in the short term. However, little is known about possible long-term side effects. Elephants 
are social animals that live in matriarchal herds, and inhibiting individual fertility and herd growth may have 
unforeseen longer-term consequences on behaviour and social structure. There is also a fear that immunization 
may favour weaker animals by preferentially sterilizing individuals capable of mounting a vigorous immune 
response, or that animals may become resistant to vaccination. In short, while pZP vaccination appears to be 
a promising tool for controlling elephant population growth, questions about the long-term side effects need 
to be answered before use on a large scale can be recommended.
Résumé
Lʼ immuno-contraception est un des moyens proposés pour la gestion des populations dʼéléphants qui menacent 
de dépasser les capacités dʼune réserve de faune. A ce jour pourtant, la seule technique dʼimmuno-contraception 
testée sur des femelles éléphants est le vaccin porcin contre la zone pellucide (pZP), une injection de pZP soluble 
et dʼun adjuvant pour induire la formation dʼanticorps contre la zone pellucide, qui bloque la fertilisation. Une 
révision de la littérature traitant de lʼutilisation de la vaccination pZP chez des mammifères en liberté révèle 
que lʼeffet contraceptif a une efficacité qui va de 22% à 100% (15 essais, deux chez lʼéléphant). Un vaccin 
pZP peut être administré par fléchette, mais pour le moment, il faut plus dʼune inoculation pour garantir le 
taux dʼanticorps contraceptifs. Les premières études montrent que la vaccination pZP est sans danger pour 
les éléphants, même pour les femelles enceintes, quʼelle ne passe pas par la chaîne alimentaire et quʼelle est 
réversible, en tout cas à court terme. Cependant, on sait peu de choses de ses effets secondaires à long terme. 
Les éléphants sont des animaux sociables qui vivent en groupes matriarcaux, et le fait dʼempêcher la fertilité 
DISCUSSION
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Introduction
In 1967, it was decided that the Kruger National Park 
(KNP) elephant population should be restricted to ap-
proximately 7000 individuals, the estimated carrying 
capacity of the park (Van Aarde et al. 1999; Whyte 
et al. 1999). As a direct consequence, in excess of 
17,200 elephants were culled or relocated between 
1967 and 1996 (Van Aarde et al. 1999). However, in 
1995 the park stopped culling as a result of public 
disapproval (Cumming et al. 1997; Fayrer-Hosken et 
al. 1997, 1999; Van Aarde et al. 1999), and the number 
of elephants has been rising ever since. Worryingly, 
some studies have concluded that the resulting high 
elephant densities will lead to habitat destruction 
(Cumming et al. 1997; Fayrer-Hosken et al. 1999; 
Whyte et al. 1999; Fayrer-Hosken et al. 2000) and 
threaten the survival of other species (Cumming et al. 
1997; Whyte et al. 1999), thereby reducing biologi-
cal diversity (Cumming et al. 1997; Van Aarde et al. 
1999; Whyte et al. 1999). Although this conclusion 
is disputed (Van Aarde et al. 1999), KNP and other 
wildlife reserve managements now widely accept that 
a high elephant density may negatively influence a 
parkʼs other flora and fauna, and they are investigat-
ing measures to maintain stable ʻoptimum  ʼelephant 
populations (Van Aarde et al. 1999).
Effectively, there are only two ways to actively 
manage the size of an animal population: increase the 
rate of removal, usually by death, or reduce the rate 
of addition, usually births (Kirkpatrick and Rutberg 
2001). Currently, the numbers of elephants in the 
larger southern African parks are too large for reloca-
tion to be considered practical and culling is subject 
to an ongoing ethical debate (Whyte et al. 1999). For 
these reasons, attention has recently focused on the 
development of techniques for reducing the birth rate, 
usually by contraception.
Similar problems with overabundant wild or feral 
species in protected reserves have previously arisen in 
the USA. Once hunting and trapping ceased to be con-
sidered acceptable by the public, non-lethal ways of 
controlling population growth were sought and stud-
ies on non-invasive contraceptive techniques were 
initiated (Kirkpatrick and Rutberg 2001). Although 
a number of different approaches were examined, 
namely 1) non-hormonal chemicals, 2) steroid hor-
mones, 3) non-steroid hormones, 4) barrier methods 
and 5) immunocontraception, the first four were, for 
various reasons, found unsuitable (Kirkpatrick and 
Rutberg 2001). As a result, immunocontraception 
was singled out for further investigation. Since some 
forms of immunocontraception, notably porcine zona 
pellucida (pZP) vaccination, have proven reliable and 
safe for controlling population growth in ungulates 
and horses, they were obvious candidates when start-
ing contraception studies in elephants.
Review and discussion
Immunocontraception
Immunocontraception is based on the same principles 
as disease prevention by vaccination. In this instance, 
however, vaccination stimulates the immune system 
to produce antibodies against endogenous molecules 
that play an essential role in either gamete production 
or fertilization, rather than against micro-organisms 
(Fayrer-Hosken et al. 2000; Kirkpatrick and Rutberg 
2001). Although there may be many possible target 
molecules for immunocontraception, the two that have 
received most attention are zona pellucida (ZP) pro-
teins and gonadotrophin-releasing hormone (GnRH). 
GnRH is the hypothalamic neuropeptide that controls 
the reproductive endocrine system; successful vacci-
nation against GnRH powerfully inhibits reproductive 
function, essentially returning treated animals to a 
pharmacological prepuberty (Stout and Colenbrander 
2004). Vaccination against ZP proteins makes use of 
the fact that ZP, an extracellular matrix surrounding 
the oocyte (Kirkpatrick and Turner 1991; Muller et al. 
1997; Barber and Fayrer-Hosken 2000b), plays critical 
roles in regulating sperm binding, penetration and fer-
tilization (Barber and Fayrer-Hosken 2000a). Although 
individuelle et la croissance du groupe peut avoir à long terme des conséquences imprévues sur le comporte-
ment et la structure sociale. On peut aussi craindre que lʼimmunisation puisse favoriser des animaux plus 
faibles en stérilisant de préférence les individus capables de manifester une réponse immunitaire vigoureuse, 
ou que les animaux deviennent résistants au vaccin. En brèf, si le vaccin pZP semble un outil prometteur 
pour contrôler la croissance des populations dʼéléphants, il faut dʼabord répondre aux questions sur les effets 
secondaires à long terme avant de pouvoir en recommander lʼusage à grande échelle.
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the exact mechanism of infertility induced by ZP vac-
cination may differ between species and individuals, 
it appears that antibodies raised against ZP proteins 
either directly block sperm–ZP binding or disrupt ZP 
formation and thereby indirectly inhibit the ability of 
sperm to bind and penetrate (Muller et al. 1997; Miller 
et al. 2000; Kirkpatrick and Rutberg 2001); in either 
case the end result is temporary infertility (Barber and 
Fayrer-Hosken 2000a; Powel and Monfort 2001). On 
the other hand, because ZP vaccination blocks fertiliza-
tion, vaccinated females should continue to experience 
regular ovarian cycles, including oestrus and ovulation 
(Barber and Fayrer-Hosken 2000a).
Porcine zona pellucida is currently the active 
ingredient of choice for ZP vaccination of wildlife 
species because it can be harvested in large quantities 
from the ovaries of slaughtered pigs and the antibodies 
induced recognize ZP epitopes in many target species 
(Fayrer-Hosken et al. 1997, 1999; Barber and Fay-
rer-Hosken 2000a, 2000b). Initial evidence that pZP 
vaccination might be an effective contraceptive for 
elephants was provided by an immunohistochemical 
study demonstrating that antibodies raised against 
pZP in rabbits also recognize epitopes in elephant 
ZP (Fayrer-Hosken et al. 1997, 1999, 2000). Recent 
studies have examined the possibility of producing 
synthetic subunit ZP vaccines. They would offer bet-
ter biosecurity by lowering the risk of transmitting 
micro-organisms between species and could more 
specifically target molecules involved in sperm–ZP 
binding and therefore reduce the risk of inducing 
generalized ovarian destruction.
An important part of both the GnRH and the 
pZP vaccines, and indeed vaccines in general, is 
the adjuvant. The adjuvant enhances the efficacy of 
vaccination by stimulating the immune system to 
produce larger concentrations of antibodies against 
the target antigen. Not surprisingly then, the efficacy 
of both GnRH (Stout and Colenbrander 2004) and 
pZP (Lyda et al. 2005) vaccination varies markedly 
depending on the adjuvant used. On the other hand, 
effective adjuvants are often ʻaggressive  ʼ and may 
induce significant injection-site swellings, includ-
ing abscess formation, or systemic reactions such as 
fever and anaphylaxis. For example, although Fre-
undʼs complete adjuvant (FCA) (Muller et al. 1997; 
Kirkpatrick and Rutberg 2001; Lyda et al. 2005) is a 
highly effective accompaniment to pZP vaccination it 
has been associated with significant adverse reactions, 
such as injection site and systemic granulomatous in-
flammation (Harrenstien et al. 2004). FCA also has a 
second specific disadvantage in that it can trigger false 
positive tuberculosis test results in vaccinated animals 
(Lyda et al. 2005). For these reasons, more recent pZP 
vaccination studies have concentrated on less aggres-
sive adjuvants, such as Freundʼs incomplete adjuvant 
(FIA), Freund sʼ modified adjuvant (FMA) (Lyda et al. 
2005) or a synthetic trehalose dicorynomycolate (S-
TDCM) adjuvant (Fayrer-Hosken et al. 1997, 1999; 
Bertschinger et al. 2003).
Brief history of ZP vaccination
Zona pellucida vaccine was first patented as a con-
traceptive agent in 1976, and the first field trials in 
free-ranging feral horses followed in 1988–1989 
(Kirkpatrick et al. 1997; Kirkpatrick and Rutberg 
2001; Kirkpatrick and Turner 2003). In the early 
years, studies focused predominantly on whether 
ZP immunization was contraceptive, and how many 
inoculations were required to achieve infertility. 
Subsequent studies investigated other aspects of im-
munization such as long-term side effects on health 
and behaviour, and more efficient delivery methods 
(Kirkpatrick and Rutberg 2001; Miller et al. 2001).
The first elephants to be treated with pZP were 
zoo animals. The initial study aimed to establish an 
effective dose and inoculation protocol, and the results 
were sufficiently promising for the South African 
National Parks Board, KNP and the Humane Society 
of the United States to design a field trial to examine 
the safety and efficacy of pZP vaccination in wild ele-
phants (Fayrer-Hosken et al. 1997, 2000; Kirkpatrick 
and Rutberg 2001; Bertschinger et al. 2003). While the 
results of the field trial, at least in terms of short-term 
safety and efficacy, were also promising (Fayrer-
Hosken et al. 1997, 2000), there are still considerable 
hurdles to negotiate. For example, Whyte (2003) pre-
dicted that to stabilize a large elephant population, 75% 
of all breeding females would need to be continuously 
contracepted; even this assumes no compensatory 
improvement in fertility among non-contracepted 
animals. Moreover, repeated immunization of large 
numbers of elephants may be financially impossible 
for many parks or conservation agencies. Neverthe-
less, research into more efficient vaccination protocols 
and the effects on behaviour continues (Delsink et 
al. 2003), because immunocontraception may be an 
affordable management option for smaller parks with 
100 cows or fewer (Bertschinger et al. 2003).
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Prerequisites for an immunocontraceptive
To objectively assess the suitability of putative con-
traceptives for use in wildlife species, it is essential 
to be clear about the prerequisites to which a ʻgold 
standard  ʼcontraceptive should conform (Frayne and 
Hall 1999; Kirkpatrick and Rutberg 2001). Here we 
will examine pZP vaccination, and in particular initial 
results from elephant studies, in terms of whether the 
following criteria for an acceptable contraceptive are 
met (Kirkpatrick and Turner 1991; Kirkpatrick and 
Rutberg 2001):
• contraceptive effectiveness of at least 90%
• the capacity for remote delivery with no (or mini-
mal) handling of animals
• reversibility of contraceptive effects
• safety for use in pregnant animals
• absence of significant health side effects
• no passage of the contraceptive agent through the 
food chain
• minimal effects upon individual and social behav-
iour
• low cost
Contraceptive efficacy of at least 90%
Reported contraceptive efﬁ cacy of pZP vaccination 
varies considerably, although results can be difﬁ cult 
to compare because they are often expressed differ-
ently, for example, as a percentage of animals failing 
to become pregnant or as a percentage reduction in 
the pregnancy rate between a treated and a control 
population (table 1). In non-elephant species, con-
traceptive efﬁ cacy of pZP vaccination has varied 
dramatically with reports of between 78% and none 
of the treated animals giving birth during the treat-
ment period (Kirkpatrick et al. 1990, 1997; Turner 
et al. 1992, 1996a, 1996b; McShea et al. 1997). The 
two elephant studies reported to date have recorded 
post-vaccination pregnancy rates of 44% and none 
among immunized cows (Fayrer-Hosken et al. 2000; 
Delsink et al. 2003).
Capacity for remote delivery with no or 
minimal handling of animals
Essentially, there are two ways to immunize a wild 
animal without needing to restrain it: oral delivery or 
remote delivery using an injection dart or a biodegrad-
able ʻbulletʼ. The major drawbacks of oral vaccine 
delivery are the need to ensure that the vaccine is not 
destroyed by the digestive system (Muller et al. 1997; 
Kirkpatrick and Rutberg 2001) and difficulty in en-
suring that a targeted individual receives the vaccine. 
The risk of inadvertently contracepting a non-target 
animal or species would also be unacceptably high 
(Kirkpatrick and Rutberg 2001). For vaccination by 
dart or bullet, the antigen (such as pZP) and adjuvant 
must be loaded to ensure effective delivery following 
impact (Muller et al. 1997). Even then, one of the 
great disadvantages in large populations requiring 
prolonged contraception is the need to administer mul-
tiple boosters to individual animals (Fayrer-Hosken 
et al. 1999; Kirkpatrick and Rutberg 2001; Pimm and 
Van Aarde 2001; Bertschinger et al. 2003; Delsink et 
al. 2003). To overcome this obstacle, recent studies 
have focused on developing single-administration 
immunization protocols (Kirkpatrick et al. 1997; 
Turner et al. 1997; Kirkpatrick and Rutberg 2001). 
The key to such protocols has been the development 
of biodegradable and non-toxic microspheres or pel-
lets into which not only can the antigen and adjuvant 
be loaded (Muller et al. 1997; Frayne and Hall 1999; 
Kirkpatrick and Rutberg 2001), but for which the rate 
of degradation can be engineered to enable release 
of a dose of vaccine after a predictable delay (Kirk-
patrick and Rutberg 2001; Kirkpatrick 2003). In early 
trials with pZP vaccine in biodegradable polymers, a 
single inoculation achieved anti-pZP antibody titres 
or degree of contraception comparable with two 
inoculations of conventional vaccine (Turner et al. 
2001; Liu et al. 2005). Moreover, since Liu et al. 
(2005) were able to raise anti-ZP antibody levels in 
horses to contraceptive levels for at least 43 weeks, 
the development of an additional pellet that would 
release antigen nine months after introduction would 
allow two years of contraception to be achieved from 
a single inoculation (Kirkpatrick and Rutberg 2001). 
Proof that longer-lasting contraception from a single 
administration is possible was provided by a study 
in which contraception lasting about six years was 
achieved in grey seals injected with pZP packaged in 
liposomes (Kirkpatrick and Rutberg 2001). On a cau-
tionary note, there are concerns that single-inoculation 
vaccines designed to immunize for longer periods 
by slow continuous release of antigen may lead to 
immunotolerance, instead of maintaining antibody 
concentrations at contraceptive levels (Kirkpatrick 
et al. 1997).
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Reversibility of contraceptive effects
An important prerequisite for a wildlife contraceptive 
is reversibility. Ideally, it should be possible to allow a 
population to resume reproduction at short notice, such 
as immediately following an unexpected population 
crash. In theory, contraception resulting from pZP or 
other antifertility vaccines will be reversed automati-
cally once circulating antibody concentrations drop 
below a threshold (Barber and Fayrer-Hosken 2000b. 
And in studies with horses, pZP vaccination for up to 
four years has been shown to be reversible (Turner, 
Kirkpatrick, et al. 1996; Kirkpatrick et al. 1997; Miller 
et al. 2000; Kirkpatrick and Rutberg 2001; Miller et al. 
2001; Powel and Monfort 2001). Observations of pZP 
vaccination in elephants have also confirmed the return 
of fertility approximately one year after a course of 
three vaccinations (Whyte et al. 1998; Fayrer-Hosken 
et al. 2000). However, in horses vaccinated for longer 
periods of time, recovery of fertility was delayed for up 
to four years (McShea et al. 1997; Miller et al. 2000), 
because pZP immunization resulted in a decline in the 
subsequent ovulation rate (Kirkpatrick et al. 1997). It is 
even more sobering to consider that in some rodent and 
primate species, ZP vaccination has been associated 
with ovarian damage characterized by depletion of the 
primordial follicle pool and disruption of foliculogen-
esis, likely to result in permanent infertility (Paterson 
et al. 1998, 1999).
Safe for use in pregnant animals
An immunocontraceptive vaccine should be safe in preg-
nant animals since, in a species with a long non-seasonal 
gestation, it is almost impossible to avoid injecting some 
pregnant animals; abortion, dystocia or birth of abnormal 
or weakened offspring would all be unacceptable side 
effects. Fortunately, studies on horses, deer, burros and 
elephants all indicate that pZP vaccination has no visible 
or measurable detrimental effects on ongoing pregnan-
cies, and harms neither the foetus nor its dam (Turner, 
Liu, et al. 1996; Kirkpatrick et al. 1997; Fayrer-Hosken 
et al. 1999, 2000; Turner et al. 1999; Kirkpatrick and 
Rutberg 2001; Delsink et al. 2003).
Absence of significant health side effects
Injection site reactions following pZP vaccination 
(Turner et al. 1996; Nettles 1997) can be serious 
enough to result in lameness and abscesses (Turner 
et al. 1997; Fayrer-Hosken et al. 1999). However, no 
other dramatic effects on health have been reported 
and, to date, there is no evidence that porcine viruses 
or other microbes have been transmitted by ZP vac-
cines. Nevertheless, the potential risks of disease 
transmission by such a biological product have 
stimulated work on synthetic vaccines (Kirkpatrick 
and Rutberg 2001).
One major caveat regarding the safety of pZP 
vaccine is that relatively little is known about the 
long-term effects of repeated treatment or the asso-
ciated changes in ovarian activity on overall health 
and behaviour (Kirkpatrick et al. 1992, 1997; Miller 
et al. 2001; Pimm and Van Aarde 2001). Elephants 
may present a particular challenge in this respect, 
because of their extreme longevity and complex social 
organization.
No passage of the contraceptive agent 
through the food chain
Conventional pZP vaccine does not appear to pass 
through the food chain (Kirkpatrick et al. 1990; Turner 
Liu, et al. 1996; Kirkpatrick and Rutberg 2001). The 
risk of a slow-release biodegradable ZP vaccine 
inducing contraception after ingestion is also likely 
to be minimal.
Minimal effects upon individual and social 
behaviour
One big concern in elephants is the possible effect 
of contraception on individual and social behaviour. 
The use of reproductive steroid hormones as contra-
ceptives proved unacceptable in wildlife because of 
marked effects on behaviour, such as separation of 
treated animals from the family herd (Fayrer-Hosken 
et al. 2000; Kirkpatrick and Rutberg 2001). To date, 
there have been no reports of obvious detrimental 
effects of pZP vaccination on social behaviour 
(Kirkpatrick et al. 1997; Fayrer-Hosken et al. 2000; 
Kirkpatrick and Rutberg 2001; Powel and Monfort 
2001). On the other hand, ZP vaccination does affect 
reproductive behaviour. In this respect, it is generally 
assumed that vaccination will not alter reproductive 
hormone secretion (Powel and Monfort 2001) and 
that treated females will therefore experience normal 
ovarian cycles (Barber and Fayrer-Hosken 2000). 
However, while some studies have indeed recorded 
normal oestrous cyclicity following ZP vaccination 
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(Fayrer-Hosken et al. 2000; Kirkpatrick and Rutberg 
2001), others have recorded abnormalities such as:
• altered ovarian function in horses (Kirkpatrick et 
al. 1992) and deer (Miller et al. 2001)
• altered cyclicity in primates (Nettles 1997) and 
deer (Muller et al. 1997)
• reduced ovulation rate in horses (Kirkpatrick et 
al. 1992, 1997)
• decreased oestrogen production in baboons (Miller 
et al. 2001) and horses (Kirkpatrick et al. 1997)
• altered ovarian structure in primates (Nettles 
1997)
• follicular inflammation in deer (McShea et al. 
1997)
• acyclicity in horses (Muller et al. 1997)
The effects on cyclicity tend to become more severe 
with the duration of elevated anti-pZP antibody titres, 
but it is not clear whether failure to cycle is advanta-
geous or disadvantageous for health and behaviour.
With regard to social behaviour, African elephants 
live in stable groups consisting of related adult females 
and their offspring. Young bulls leave the herd shortly 
after reaching sexual maturity and go off to live in bull 
groups or in solitude (Rasmussen and Schulte 1998). 
Adult males really interact with the matriarchal herds 
only when a female is in oestrus and ready for mating 
(Moss 1983). One obvious consequence of contraception 
is that the number of offspring born into a herd will de-
crease or stop, and as yet, it is not clear whether this will 
affect group behaviour (Rasmussen and Schulte 1998; 
Fayrer-Hosken et al. 1999). The other major change 
expected after ZP vaccination is an increased frequency 
of oestrous cycles, and therefore of interaction with 
adult bulls. The oestrous cycle of an elephant cow lasts 
12 to 18 weeks (Rasmussen and Schulte 1998). During 
this cycle the cow has a 2- to 10-day period of sexual 
receptivity when she will show oestrous behaviour, ac-
cept mating and may conceive (Moss 1983; Rasmussen 
and Schulte 1998). A female elephant announces her 
sexual receptivity in advance through chemical, auditory 
and behavioural signals, increasing the likelihood that 
a desirable bull will present himself for mating; bulls 
will travel great distances to find an oestrous female 
(Rasmussen and Schulte 1998).
In the event of pregnancy, the cow will not cycle 
again for at least another two years, the length of 
gestation (Rasmussen and Schulte 1998). Because 
sexually receptive periods usually end with mat-
ing and pregnancy (Rasmussen and Schulte 1998), 
repeated oestrous cycles are not a normal feature of 
wild elephant reproduction. It is, therefore, not clear 
how an increase in the number of oestrous cycles due 
to immunocontraception will affect male behaviour, 
or how much the disruption caused by more frequent 
bull attention will affect the matriarchal groups. In 
brush-tail possums, increased numbers of oestrous 
females led to an increase in the number of visiting 
males (Ji et al. 2000), whereas in deer an increase 
in the number of oestrous females led to a reduction 
in interest among the dominant males (Miller et al. 
2001). The effects on female elephants of repeated 
oestrus and failure to produce a calf at the expected 
interval are similarly difficult to predict.
Low cost
For large-scale use in wildlife populations an ideal 
contraceptive should be low cost. Indeed, Whyte et 
al. (1998) warned that immunocontraception may be 
unsuitable for use in large elephant populations or 
large conservation areas because of the logistics and 
costs. Pimm and Van Aarde (2001) calculated that 
the costs of controlling the KNP elephant popula-
tion by pZP immunocontraception would exceed the 
total management budget for South African National 
Parks. On the other hand, Fayrer-Hosken et al. (2001) 
point out that the cost and the speed of field deliv-
ery have not really been assessed in large groups of 
elephants, and that pZP immunocontraception has 
proven affordable for managing herds of horses and 
deer. Certainly, development of a one-shot vaccine 
would dramatically simplify the logistics and reduce 
the costs of immuno-contraception (Fayrer-Hosken 
et al. 2001).
Genetic selection and resistance
Immunocontraception may be selective. In theory, 
healthy animals with a vigorous immune response 
are more likely to become infertile than individuals 
with a weak or compromised immune system (Muller 
et al. 1997; Nettles 1997; Miller et al. 2001). If this 
is true in practice, immunocontraception would es-
sentially favour animals with poor disease resistance, 
and encourage reproduction among the least ʻgeneti-
cally fitʼ. However, while Muller et al. (1997) claim 
that genetics play an important role in the antibody 
response to vaccination, Kirkpatrick et al. (1997) 
maintain that an individualʼs response to pZP is 
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more closely related to dose, adjuvant and route of 
administration than to immune competence. In the 
longer term, it is also possible that natural selection 
may favour individuals genetically resistant to a 
contraceptive agent, although the risk of resistance 
could be minimized by developing multiple vaccines 
with slightly different activities for use in rotation or 
combination (Magiafoglou et al. 2003).
Opinion and recommendations
The current challenge is to determine whether immu-
nocontraception can be responsibly and economically 
used to manage African elephant populations. If pZP 
can be proven to satisfy all the listed criteria, it needs 
to be considered a realistic alternative for managing 
elephant population growth. Unfortunately, this is a 
utopian view that does not take into account the moral 
and social dilemmas associated with the elephantʼs 
status as a highly intelligent and sensitive keystone 
species, or its inhabitance of areas that are also home 
to millions of the worldʼs poorest people.
In both elephants and other species, the apparent 
success of immunocontraception varies greatly (table 
1). These differences in efficacy may be largely attrib-
utable to differences in immunization protocol; more 
boosters generally result in more effective contracep-
tion. However, repeated immunization of individual 
wild elephants would be problematic because it re-
quires identification with a radio collar, and tracking 
at set intervals. Not only would this be difficult and 
costly, but repeated darting is likely to be stressful to 
the animals and may make them more wary of people or 
aggressive towards them. The development of a one-
inoculation vaccine is thus an imperative if immuno-
contraception is to become a realistic proposition for 
medium to large elephant populations.
There are also arguments about how accurate calcu-
lations of contraceptive effectiveness really are. Some 
studies report efficacy in terms of a reduction in preg-
nancy rates or population growth rate in comparison 
with a control population, while others use the number 
of vaccinated females that give birth. While both meth-
ods have their pros and cons, the choice of one over 
the other is the basis of some ongoing disagreements. 
For example, Pimm and Van Aarde (2001) have sug-
gested that Fayrer-Hosken et al. (2000) exaggerated the 
effectiveness of pZP contraception in elephants because 
their control group had unusually high pregnancy rates 
(16/18 = 89%). In a larger sample of 813 adult cows 
culled in KNP between 1979 and 1994 an average of 
51% (range 36–77%) of adult females were pregnant. 
Pimm and Van Aarde (2001) argue that this lower 
figure is a much more realistic basis for comparison, 
since it is closer to what would be predicted on the 
basis of the 22-month gestation and 44-month calving 
interval typical of African elephants.
One of the most important reasons for not yet 
recommending widespread implementation of pZP 
vaccination in elephants is the uncertainty surrounding 
long-term safety and reversibility: a number of studies 
have reported either ovarian damage (Paterson et al. 
1999) or reduced or delayed return to ovarian function 
(Muller et al. 1987) after ZP vaccination. Clarity over 
the effects of longer-term administration is particularly 
pertinent to elephants because of their extreme longev-
ity. Moreover, even if vaccination does not directly 
damage the ovaries, there are indications that long 
non-reproductive periods may accelerate the onset of 
reproductive senescence in elephant cows (Hermes et 
al. 2004). While it is similarly difficult to predict the 
effects of long periods of infertility on  elephant social 
behaviour, it is clear that repeatedly vaccinating all the 
adult females in a matriarchal group would eventually 
lead to the collapse of that herd. Any large-scale con-
traceptive programme for elephants will therefore have 
to be carefully designed and regularly updated to avoid 
collapse of herds due to dwindling numbers.
Of course, the costs and logistics of immunocon-
traception are likely to remain the greatest obstacle to 
implementation in large elephant populations. And while 
a reliable one-inoculation immunization protocol will 
obviously simplify the operation and dramatically reduce 
costs, it is possible that elephant immunocontraception 
may still be viable only in smaller conservation areas, 
where elephant numbers are low but population growth 
and densities are relatively high (Slotow et al. 2005; Van 
Aarde and Jackson 2007).
In conclusion, available evidence suggests that 
pZP vaccine is an effective contraceptive for ele- 
phants that can be delivered remotely, is safe to use 
in pregnant animals, does not pass through the food 
chain, and is reversible, at least after short durations of 
vaccination. However, before ZP vaccination can be 
recommended for wide-scale use in elephant popula-
tion control additional studies are needed to elucidate 
effects on health, behaviour and reversibility after 
longer periods of administration.
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